Artiva Biotherapeutics, Inc.’s (NASDAQ:ARTV) Lock-Up Period To Expire on January 15th

Artiva Biotherapeutics’ (NASDAQ:ARTV) lock-up period is set to expire on Wednesday, January 15th. Artiva Biotherapeutics had issued 13,920,000 shares in its IPO on July 19th. The total size of the offering was $167,040,000 based on an initial share price of $12.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period.

Analyst Ratings Changes

Several brokerages have recently weighed in on ARTV. Needham & Company LLC reiterated a “buy” rating and set a $23.00 price target on shares of Artiva Biotherapeutics in a research report on Wednesday, November 13th. HC Wainwright initiated coverage on shares of Artiva Biotherapeutics in a research note on Monday, December 30th. They set a “buy” rating and a $20.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $21.00.

Artiva Biotherapeutics Stock Performance

Shares of NASDAQ ARTV opened at $9.35 on Friday. The business has a 50-day simple moving average of $11.34. Artiva Biotherapeutics has a twelve month low of $9.30 and a twelve month high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.24). Research analysts forecast that Artiva Biotherapeutics will post -4.68 EPS for the current fiscal year.

Institutional Trading of Artiva Biotherapeutics

A number of hedge funds have recently made changes to their positions in the stock. RA Capital Management L.P. bought a new position in Artiva Biotherapeutics in the third quarter valued at $152,234,000. Franklin Resources Inc. bought a new position in shares of Artiva Biotherapeutics during the 3rd quarter valued at about $7,435,000. Geode Capital Management LLC purchased a new position in shares of Artiva Biotherapeutics during the 3rd quarter valued at about $4,774,000. Samsara BioCapital LLC bought a new stake in Artiva Biotherapeutics in the 3rd quarter worth approximately $4,506,000. Finally, Wellington Management Group LLP purchased a new stake in Artiva Biotherapeutics in the third quarter worth approximately $2,912,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.